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Abstract
Introduction: Antiretroviral treatment (ART) reduces HIV transmission. Despite increased ART coverage, incidence remains
high among men who have sex with men (MSM) in many places. Acute HIV infection (AHI) is characterized by high viral
replication and increased infectiousness. We estimated the feasible reduction in transmission by targeting MSM with AHI for
early ART.
Methods: We recruited a cohort of 88 MSM with AHI in Bangkok, Thailand, who initiated ART immediately. A risk calculator
based on viral load and reported behaviour, calibrated to Thai epidemiological data, was applied to estimate the number of
onwards transmissions. This was compared with the expected number without early interventions.
Results: Forty of the MSM were in 4th-generation AHI stages 1 and 2 (4thG stage 1, HIV nucleic acid testing (NAT)+/4thG
immunoassay (IA)-/3rdG IA–; 4thG stage 2, NAT+/4thG IA+/3rdG IA–) while 48 tested positive on third-generation IA but had
negative or indeterminate western blot (4thG stage 3). Mean plasma HIV RNA was 5.62 log10 copies/ml. Any condomless sex
in the four months preceding the study was reported by 83.7%, but decreased to 21.2% by 24 weeks on ART. After ART, 48/
88 (54.6%) attained HIV RNA <50 copies/ml by week 8, increasing to 78/87 (89.7%), and 64/66 (97%) at weeks 24 and 48,
respectively. The estimated number of onwards transmissions in the first year of infection would have been 27.3 (95%
credible interval: 21.7–35.3) with no intervention, 8.3 (6.4–11.2) with post-diagnosis behaviour change only, 5.9 (4.4–7.9)
with viral load reduction only and 3.1 (2.4–4.3) with both. The latter was associated with an 88.7% (83.8–91.1%) reduction in
transmission.
Conclusions: Disproportionate HIV transmission occurs during AHI. Diagnosis of AHI with early ART initiation can substantially
reduce onwards transmission.
Keywords: HIV; acute infection; men who have sex with men; models/projections; prevention of sexual transmission;
behavioural interventions; antiretroviral therapy
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Introduction
Antiretroviral treatment (ART) reduces HIV viral load and
HIV transmission in HIV-discordant heterosexual couples
[1–6]. However, despite increased uptake of ART since
1996, HIV incidence continues to rise among men who
have sex with men (MSM) globally [7,8]. Fisher and collea-
gues reported a longitudinal phylogenetic analysis of HIV-1
in a UK MSM cohort from a population with a rising HIV
epidemic in which onwards HIV transmission is significantly
associated with recent infection, and the majority of new
infections appear to occur from individuals who were as yet
undiagnosed, and thus prior to initiating ART [9]. These
findings are confirmed by multiple phylogenetic studies in
MSM cohorts in Denmark, Switzerland, Canada, the USA
and China [10–16]. While such phylogenetic studies are
lacking in the Thai MSM population, newly HIV-infected
MSM in Bangkok, Thailand, are mostly young men con-
nected to circles of highly sexually active young MSM in a
multi-risk factor environment, including high partner turn-
over, stimulant drug use, concurrent sexually transmitted
infections (STIs) and unidentified newly HIV-infected other
MSM [17].
Acute HIV infection (AHI) is characterized by high viral
replication in blood and genital secretions and hence
increased infectiousness to which characteristics of founder
viruses may also contribute [18–26]. Here, we describe
observed reductions in HIV-1 plasma viral load and trans-
mission risk behaviour in a cohort of acutely infected Thai
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MSM. We use an HIV risk calculator model, calibrated to
reflect HIV incidence and prevalence among Thai MSM and
informed by published data on the relationship between
viral load and transmission risk and observed data from the
cohort, to estimate the impact of viral load control and
behavioural change on epidemic spread through interven-
tions targeting Thai MSM at high risk.
Methods
Study design
Study RV254/SEARCH 010 is a prospective cohort study
conducted in Bangkok, Thailand, which enrols predomi-
nantly Thai participants in the earliest stages of HIV-1
infection. AHI staging was based on a combination of HIV
RNA detection (nucleic acid testing (NAT) testing) 4th-gen-
eration (4thG) immunoassay (IA), third-generation (3rdG) IA
and western blot results: 4thG AHI stages 1, 2 and 3 (4thG
stage 1, NAT+/4thG IA-/3rdG IA–; 4thG stage 2, NAT+/4thG
IA+/3rdG IA–; 4thG stage 3, NAT+/4thG IA+/3rdG IA+/wes-
tern blot– or indeterminate) [27]. Both 4thG and 3rdG IAs
detect IgM, but the 4thG assay also detects p24 antigen.
Between April 2009 and March 2013, 69,911 samples were
screened to identify 112 acutely infected participants and
100 enrolled: 90 MSM, 8 heterosexual women and 2 het-
erosexual men. Two of the MSM opted to not start ART
immediately. Here we include data from the 88 MSM
enrolled and treated with immediate ART, all of whom
had reached beyond 24 weeks on study at time of analysis.
Clinical, immunological and virological characteristics of the
study participants are primary endpoints and have been
described in several publications [27–32]. The study also
collects descriptive data of demographics and behavioural
risk, and characteristics of sexual contacts. Study interven-
tions include immediate ART upon diagnosis and beha-
vioural counselling. Outcomes measured are markers of
disease progression, including CD4+ T cell count, HIV RNA
in blood and behavioural changes. Plasma HIV RNA data
and behavioural data were used in a risk calculator model
(described below) to estimate the number of onwards
transmissions averted from this cohort due to detection
of AHI, behaviour change and ART initiation. The study is
registered at clinicaltrials.gov (NCT00796146) and is
approved by the institutional review boards (IRBs) of
Chulalongkorn University, Thailand, and Walter Reed Army
Institute of Research, USA. All participants gave informed
consent. Participants who elected to start immediate ART
were co-enrolled in a local protocol (clinicaltrials.gov:
NCT00796263) approved by the Chulalongkorn
University IRB.
Setting and participants
Participants who presented for voluntary HIV counselling
and testing (VCT) with 4thG IA at two sites in Bangkok,
Thailand (the Thai Red Cross Anonymous Clinic and Silom
Community Clinic) and gave informed consent had blood
samples screened for AHI by pooled HIV NAT and sequen-
tial IA according to published methods [27,32]. AHI was
defined as either being 4thG IA positive with positive HIV
RNA and negative or indeterminate western blot, or 4thG IA
negative while testing positive for HIV RNA by both quali-
tative (NAT) and quantitative (HIV RNA) assays. Any VCT
client aged 18 years or older with confirmed AHI is eligible
for study RV254/SEARCH 010 screening. ART for all partici-
pants opting for immediate treatment includes efavirenz,
tenofovir and emtricitabine or lamivudine, with or without
raltegravir and maraviroc. Substitution with an integrase or
protease inhibitor is used for participants with efavirenz
intolerance.
Laboratory methods
HIV RNA was measured in plasma at baseline and weeks 2,
4, 8, 12, 16, 20, 24 and every three months thereafter by
either the COBAS® AMPLICOR HIV-1 Monitor Test v1.5
(Roche Molecular Systems, Inc., Pleasanton, CA, USA) or
the COBAS®AmpliPrep/COBAS® TaqMan® HIV-1 test v2.0
(Roche Molecular Systems, Inc., Pleasanton, CA, USA) with
analyses based on lower limit of detection of 50 copies/ml.
Measures
The number and type of sexual partners (steady, casual),
condom use and specific sexual behaviours were assessed
by standardized written questionnaires asking quantifying
information which were completed by participants in a
private setting at baseline, week 24 and week 48. . The
questionnaire asked data about number of partners; oral/
anal intercourse practices, role (receptive, insertive or both)
and condom use; and knowledge about HIV sero-status of
each partner in the preceding four months.
Questions regarding behavioural practices, such as
unprotected anal intercourse, were asked as part of stan-
dard medical history from each participant by the study
physicians at each visit. If crucial information was missing
from either questionnaire or medical history, these were
supplemented by each other in the final data set used for
this analysis.
Estimated date of infection was assessed from question-
naire and medical history.
Statistical and risk calculation methods
Study participants who reported sex with male partners
and opted for immediate ART were included in the analysis.
Statistical analyses were done using Stata/IC 12.1 for win-
dows (StataCorp LP, College Station, TX, USA).
Risk calculator model methods
Time-dependent individual-level plasma HIV viral load and
reported transmission-related behaviour data were used to
inform a risk-equation model. The model included the (viral
load-dependent) transmission probability per-act and fre-
quency of types of transmission-related acts. Calculations
were calibrated by adjustment of the parameter for trans-
mission probability per-act associated with viral load set
point to reflect HIV incidence estimates among MSM in
Bangkok of 5.9 infections per 100 person years (95% CI
5.2–6.8) and an HIV prevalence estimate of 23.9% (95% CI
21.1–27.0) [17]. This model was then used to estimate the
number of new HIV infections caused by each person in the
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first year after exposure. Two main scenarios were pro-
jected: (i) a baseline scenario which incorporated the inter-
ventions as reported in the data and (ii) a hypothetical
scenario with no early detection and treatment. Under
the hypothesized scenario of no early detection and treat-
ment, the viral load of each individual was assumed to
follow a standard trajectory, see Figure 1 [33].
Transmission risk behaviours of the cohort reported at
the time of diagnosis were kept constant across the simula-
tion in this counterfactual/no-intervention scenario. Two
further hypothetical scenarios were simulated: (i) a sce-
nario where only behavioural changes were considered as
reported in the cohort data and (ii) a scenario in which
behaviours were assumed to be as they were just prior to
diagnosis but viral load reduction was considered as mea-
sured in the study. These scenarios were projected to
distinguish between the influence of viral load reduction
through treatment and diagnosis-related risk behaviour
changes.
We used an adaptation of Røttingen and Garnett’s pre-
viously reported equation λ ¼ c 1 Pð Þ 1 1 β1ð Þ
n½ ,
which estimates the number of onwards infections caused
by an average infected individual over a given period of
time [34]. Here, β1 is the transmissibility of one unpro-
tected act between two individuals and n is the number
of risk acts between the individuals, c is the number of
partners of an average infected individual and P is the
prevalence of infection among the population; hence
c 1 Pð Þ represents the number of contacts without HIV.
The use of condoms and different forms of sexual contact
and associated risk behaviours can then be incorporated
into this base equation, leading to
λ ¼ c 1 Pð Þ 1 1 β1ð Þ
n 1γð Þ
1 1 εð Þβ1ð Þ
nγ
h i
where γ is the proportion of sexual acts protected by a
condom and ε is the efficiency of condom use in reducing
transmissibility.
There is a strong relationship between HIV viral load and
transmission [35,36]. Blaser et al. recently conducted a
meta-analysis of estimates around this relationship and
found a 2.09-fold (95% CI 1.47–2.97) increase in infectious-
ness per 10-fold increase in viral load amongst discordant
heterosexual couples [36]. Using this relationship, we esti-
mate the transmissibility per average unprotected act invol-








where V1 is the viral load during any particular risk event
and V0 is the average baseline viral load corresponding to a
baseline transmission probability (we take V0 to be the viral
load set point among untreated individuals and β0 is cali-
brated to reflect the incidence of HIV among MSM in
Bangkok) [17,33]. The calculated value of β0 was found to
be 0.67 (0.59–0.76). This is in reasonable agreement with
independent pooled estimates of transmission risks calcu-




Baseline characteristics of the 88 participants are summar-
ized in Table 1. At time of analysis all 88 had reached
24 weeks on study while 66/88 had reached 48 weeks on
study. Mean age at time of AHI was 28.5 years and mean
estimated duration of infection was 16.5 days. The majority
of participants were in 4thG stage 3 (n = 48), the remainder
in 4thG stages 1 (n = 19) and 2 (n = 21). Mean CD4+T cell
count was 412 cells/mm3, mean plasma HIV RNA 5.62 log10
copies/ml and the majority of participants (73%) were
infected with HIV-1 subtype CRF_01AE, the predominant
circulating form in Thai MSM [39]. Completed questionnaire
data were available for 86 participants at baseline.
Figure 1. Viral load trajectory [33].
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Any condomless sexual intercourse in the preceding four
months was reported by 72 participants (83.7%).
Condomless intercourse with regular partners, casual part-
ners, commercial sex workers, paying partners and partners
who inject drugs was reported by 55 (64%), 49 (57%), 6
(7%), 6 (7%) and 9 (10.5%) participants, respectively. None
reported abstinence from sexual intercourse in the four
months preceding the study while 10 (11.6%) reported a
single partner. Two to four partners were reported by 47
participants (54.7%) and ≥5 partners by 25 (29.1%) partici-
pants. Four participants (4.7%) declined to answer.
A large decrease in the number of sexual partners and
condomless sex was reported following HIV diagnosis. At
baseline, 72/86 (83.8%) reported multiple partners in the
preceding four months, while 10/86 (11.6%) and 0/86
reported a single or no partners, respectively, and 4
(4.6%) declined to answer. This contrasts with 43/85
(50.6%, p < 0.001) and 29/65 (44.6%, p < 0.001) reporting
a single partner or no partner at weeks 24 and 48, respec-
tively. However, 25 (29.1%) of 86 participants reported ≥5
partners in the preceding four months at baseline while 9/
65 (13.9%) reported ≥5 partners in the preceding four
months at week 48 (p = 0.06); 4/9 participants were
among the 25 who reported ≥5 partners at baseline. Any
reported condomless sexual intercourse declined from 72/
86 (83.7%) at baseline to 18/85 (21.2%) at week 24
(p < 0.0001) and 20/65 (30.8%) at week 48 (p < 0.0001)
(Figure 2); 16/18 and 18/20 at weeks 24 and 48, respec-
tively, were among the 72 who reported condomless sexual
intercourse at baseline.
Mean plasma HIV RNA decline is shown in Figure 3; 5/87
(5.7%) participants attained HIV RNA <50 copies/ml by
week 2, which increased to 48/88 (54.6%), 60/88 (68.2%),
78/87 (89.7%) and 64/66 (97%) at weeks 8, 12, 24 and 48,
respectively.
Modelling analyses
Based on viral load and transmission-related risk behaviour
of each individual within the cohort, we estimated the rate
of infectiousness per infected individual per day (Figure 4).
Figure 5 illustrates the estimated number of onwards infec-
tions from each individual over the first year compared
with expected number of transmissions without early diag-
nosis and ART.
Table 1. Baseline characteristics
Baseline characteristics of 88 MSM
Total
(n = 88)
Age (years), mean (SD) 28.5 (7.0)




Infection duration (days), mean (SD) 16.5 (6.6)
CD4T cell count (cells/mm3), mean (SD) 412 (188.7)
Plasma HIV RNA (log10copies/ml), mean (SD) 5.62 (1.00)
Baseline behaviour data N = 86
Unprotected sexual intercourse in four months prior
to study, n (%)
72 (83.7)
With regular partner 55 (64.0)
With casual partner 49 (57.0)
With commercial sex worker 6 (7.0)
With person who gives money/goods 6 (7.0)
With IVDU partner 9 (10.5)





Decline to answer 4 (4.7)
a4th-generation (4thG) AHI stages: 4thG stage 1, NAT+/4thG immu-
noassay (IA)-/3rdG IA–; 4thG stage 2, NAT+/4thG IA+/3rdG IA–;
4thG stage 3, NAT+/4thG IA+/3rdG IA+/western blot– or
indeterminate.
MSM: men who have sex with men; SD: standard deviation; IVDU:
intravenous drug user.
Figure 2. Percentage of participants reporting unprotected sexual
intercourse in preceding four months.
**p < 0.0001 vs. week 0
Figure 3. Plasma HIV RNA.
BD: below detection (<50 copies/ml).
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In the baseline (actual) scenario, the mean number of
estimated new infections caused per infected individual
over their first year of infection was 0.035, whilst in the
hypothetical scenario of no early detection and treat-
ment this value was estimated at 0.294. In the hypothe-
tical scenario where only viral load reduction is
considered (without changes to risk behaviour), the
mean number of estimated new infections caused per
infected individual was 0.066. The value for the scenario
in which only post-diagnosis behaviour changes are con-
sidered was 0.093. We also calculated potential addi-
tional second-, third- and fourth-generation
transmissions in the first year from the index cases in
the cohort. In the baseline scenario, an estimated mean
3.00 (95% credible interval: 2.31–4.18) direct infections
and 0.08 (0.06–0.11) indirect infections are caused by the
cohort one year after HIV exposure, giving a total of 3.08
(2.37–4.29) new transmissions. In the hypothetical sce-
nario of no early detection and treatment intervention,
the estimated total number of new infections caused by
the cohort after one year was 27.26 (21.68–35.26): 25.34
(20.09–32.85) direct and 1.92 (1.59–2.41) indirect trans-
missions. These results translate into an estimated 88.7%
(83.8–91.1%) reduction in onwards transmissions, one
year after HIV exposure due to early detection and treat-
ment (Figure 6).
Under the scenario of post-diagnosis behaviour change
only, an estimated 8.26 (6.39–11.24) transmissions are
caused by the cohort (approximately 70% reduction com-
pared to no intervention), whereas the number of new
infections in the viral load reduction-only scenario was
5.88 (4.42–7.91) (approximately 78% reduction compared
to no intervention).
Discussion
Our study provides evidence of substantial impact in redu-
cing HIV transmission among Thai MSM through diagnosing
Figure 4. Estimated infections per infected individual per day.
Figure 5. Estimated number of onwards HIV transmissions per infected individual during the first year of infection.
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HIV during acute infection and early initiation of ART. Post-
diagnosis behavioural changes can significantly reduce the
number of new HIV infections, but viral load reductions
through ART have the greatest impact and together are
estimated to reduce transmission by 89% over the first
year of infection.
The broader population impact of such interventions may
depend on the stage of the HIV epidemic. Current literature
estimates the fraction of HIV transmissions in urban MSM
populations resulting from AHI partners to be anywhere
from 4% to 50% [13,16,19,40–45]. The phylogenetic
approach used by Brenner and colleagues in the Quebec
PHI Cohort leads to the higher estimate of early infection
accounting for approximately half of onwards transmissions
[13]. This finding is supported by phylogenetic studies in
MSM populations elsewhere and would fit the ongoing
incidence in MSM in Bangkok with a reported 60-month
cumulative HIV incidence of 23.9% (31.3% for 18–21-year-
olds) and overall HIV incidence of 5.9 per 100 person years
[17]. It is reasonable to expect that in such a rising and
ongoing HIV epidemic, AHI detection and control may be a
powerful HIV prevention measure. We also demonstrated
that AHI detection and early ART initiation are feasible to
implement.
Benefits of treatment as prevention for MSM are con-
sidered highly plausible [1,46]. However, prevention bene-
fits may be attenuated by other factors such as increasing
condomless sex or STIs. The ongoing PARTNER and
Opposites Attract studies provide the strongest evidence
to date that treatment as prevention is indeed effective in
MSM, with no transmissions reported to date in the
PARTNER study among the sero-discordant MSM couples
in whom the HIV-positive partner had HIV RNA <200
copies/ml [47,48]. The study’s analysis estimated within-
couple risk of HIV transmission for condomless receptive
anal intercourse when ejaculation occurred to be 0 (zero)
per 100 couple years (upper 95% confidence limit 2.7)
despite an STI incidence of 17–18% among the participating
MSM. The benefit of treatment as prevention not being
negatively impacted by condomless sex or STI in these
studies, yet a high HIV incidence in some MSM commu-
nities with high ART uptake, would fit with AHI being an
important factor in transmission in these communities [47].
If so, then to meet the UNAIDS target of eliminating HIV by
2030, AHI detection and treatment would need to be prior-
itized [49]. To the best of our knowledge, there are no
studies specifically looking into treatment as prevention
which target people during AHI. Our study therefore adds
to the current literature by offering a first estimate of its
possible impact based on actually observed AHI treatment
effects.
The public health challenges of optimizing the
engagement of care cascade to facilitate treatment as
prevention strategies at the population level have been
well described, recently with focus on engaging people
with AHI [50,51]. While identifying AHI individuals
remains challenging, AHI screening yield clearly depends
on HIV prevalence in a given population and can be
cost-effectively improved by adding pooled NAT testing
to diagnostic algorithms for populations at high risk
[32,52,53]. AHI incidence at the Thai Red Cross
Anonymous Clinic was previously reported at 2.2 per
100 person years but seems to be rising after success-
fully engaging more MSM in HIV testing and counselling
through Adam’s Love, an innovative web-based commu-
nications strategy. Since its introduction, the annual
number of participants identified with AHI has increased
from 25 to over 100 at this clinic [54]. Our study adds to
a growing body of evidence that once identified, AHI
may present a unique opportunity for behavioural coun-
selling and entry into care [55–60]. We observed a
significant reduction in sexual partners and a significant
increase in condom use among study participants as
reported at 24-week follow-up on study which was sus-
tained throughout week 48, but our data cannot estab-
lish whether this was impacted by the behavioural
counselling provided in the study or might be seen
based on awareness of diagnosis alone [56–58].
Figure 6. Estimated number of onwards transmissions across the cohort over one year of infection per participant.
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While we need longer follow-up data to assert whether
the observed behavioural changes are sustained, it is very
encouraging that they are at least sustained until the vast
majority of participants have reached plasma HIV RNA
below the level of detection. Screening for AHI and linkage
to care and treatment have been routinely practised in
other settings, including North America and Australia,
showing both feasibility and cost efficacy [61–66].
Our study is subject to limitations, which should be
noted in interpreting results. The main finding of esti-
mated transmissions averted is dependent on the rela-
tionship between viral load and HIV transmission
probabilities. The relationship used was derived from
heterosexual discordant couples in latent infection but
adjusted to reflect higher transmission probability magni-
tudes for MSM in Bangkok and calibrated to local inci-
dence and prevalence data. Calculations used numbers of
self-reported transmission-related risk events, which are
subject to potential bias. Social desirability and informa-
tion bias cannot be excluded in gathering historical infor-
mation on sexual behaviour. Given the sensitive nature of
the information, we assume that self-reported beha-
vioural data may underestimate number of partners and
overestimate condom use. Standardized medical history
taking at each follow-up visit readdressed these questions
as a result of which such phenomena were minimized as
much as possible. The duration of time from infection to
diagnosis cannot be verified or estimated precisely,
regardless of evidence of acute HIV detection among
the individuals included in this study.
Conclusions
There is strong evidence that ART not only has individual
clinical benefits but also substantially reduces transmission
risk. Given the large contribution of AHI to population
incidence, we aimed to assess the potential effect of target-
ing detection of AHI in Bangkok-based MSM and initiation
of early ART. We estimated that this approach could lead to
89% reduction in HIV transmissions during the first year of
HIV infection when levels of transmission are highest. We
believe that global elimination targets by 2030 require
investment in prioritizing detection and treatment of early
HIV infection. We have provided evidence that intensive
efforts with such a strategy can lead to large changes in
transmission and thus potential epidemic reversal
among MSM.
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